Phyrago Shortage: What Providers and Prescribers Need to Know in 2026

Phyrago (dasatinib tablets, Handa Therapeutics / Cycle Pharmaceuticals) was launched in the United States in October 2025 and represents an important advance in dasatinib pharmacotherapy: it is the first and only dasatinib formulation that maintains bioavailability when co-administered with proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs). For oncology prescribers, this has significant clinical implications for the substantial proportion of CML and Ph+ ALL patients who require concomitant acid suppression therapy.

This provider-focused guide covers Phyrago's distribution model, insurance access challenges, the prior authorization landscape, and practical strategies to minimize access delays for your patients.

Clinical Rationale: Why Phyrago Over Generic Dasatinib?

The bioavailability of standard dasatinib is highly pH-dependent. Studies demonstrate a 40–60% reduction in dasatinib systemic exposure when co-administered with PPIs, and meaningful reductions with H2RAs. Given that a significant proportion of CML and Ph+ ALL patients are on these medications for GERD, esophagitis, or gastroprotection during chemotherapy, this drug-drug interaction is a clinically meaningful concern.

Phyrago's novel formulation addresses this interaction. Pharmacokinetic studies confirm that omeprazole (PPI) and famotidine (H2RA) do not significantly affect Phyrago's dasatinib bioavailability. This clinical advantage forms the primary basis for prescribing Phyrago over standard formulations and is the key argument for overcoming step therapy requirements when they are imposed by payers.

Is There a Supply Shortage of Phyrago in 2026?

As of 2026, there is no FDA-listed shortage of Phyrago and no manufacturer-reported supply disruption. The access difficulties that prescribers and patients experience are driven by the specialty distribution model, insurance access requirements, and the novelty of the product, not by supply chain issues.

Phyrago's Distribution Model

Phyrago is exclusively available through Onco360 specialty pharmacy, distributed through McKesson, Cencora, and Cardinal Health. Your practice will need to route prescriptions specifically through Onco360 or through the Cycle Vita hub program (888-360-8482). The Cycle Vita team includes dedicated patient access specialists who handle benefit verification, prior authorization, and financial assistance enrollment.

Key operational point: prescriptions sent to retail pharmacies or non-Onco360 specialty pharmacies will not be able to dispense Phyrago. Ensure your e-prescribing workflow includes Onco360 as an option, or contact your Cycle Pharmaceuticals field representative to set up the enrollment pipeline.

Prior Authorization Requirements and Payer Landscape

As a newly approved brand-name specialty oncology drug, Phyrago faces a challenging payer landscape. Key considerations for prescribers in 2026:

• Prior authorization required by nearly all plans. Submit documentation of diagnosis (Ph+ CML or Ph+ ALL), phase/stage, and the clinical rationale for Phyrago specifically.

• Step therapy through generic dasatinib is common. To override step therapy, document the patient's concurrent PPI or H2RA use and the clinical consequence of reduced dasatinib bioavailability.

• Some plans exclude brand products with available generics. The clinical distinction of Phyrago (PPI/H2RA compatibility) is the clinical differentiation that should support a medical necessity exception.

• Medicare Part D patients cannot use manufacturer copay cards. Refer these patients to independent patient assistance foundations such as the Leukemia & Lymphoma Society (LLS) co-pay assistance program or Patient Advocate Foundation.

Starter Supply: Bridging Patients While PA Is Pending

One of the most clinically important features of the Cycle Vita program is the availability of a free starter supply for commercially insured patients while prior authorization is being pursued. For newly diagnosed patients with Ph+ CML or Ph+ ALL, treatment delays can have clinical consequences. Enrolling patients in Cycle Vita at the time of prescription initiation can provide a bridge supply that keeps patients on therapy while the insurance process plays out.

Managing Patients If Phyrago Access Is Denied

If a patient cannot access Phyrago despite appeal efforts, clinical bridge options include:

• Temporary discontinuation of the PPI/H2RA if clinically feasible, allowing substitution with generic dasatinib or Sprycel

• Switching to an alternative second-generation TKI not affected by gastric pH (e.g., nilotinib, bosutinib)

• Imatinib for newly diagnosed chronic phase CML in lower-risk patients where the urgency of deep molecular response is less critical

How medfinder Supports Your Patients' Access

For your patients who are struggling to navigate pharmacy access on their own, medfinder.com/providers offers a service that calls pharmacies on patients' behalf to check availability, saving time for both patients and staff. See also our companion guide, How to help your patients find Phyrago in stock: A provider's guide.